The smart drug delivery systems market size is expected to see rapid growth in the next few years. It will grow to $25.94 billion in 2028 at a compound annual growth rate (CAGR) of 19.7%. The anticipated growth in the forecast period can be attributed to several factors, including the growing burden of non-communicable diseases, an increased focus on precision medicine, the rise of theragnostics, a growing demand for non-invasive drug delivery methods, and the continual increase in healthcare expenditure. Major trends expected during this period include advancements in miniaturization and microfabrication technologies, innovations in material science, the integration of artificial intelligence (AI) and machine learning (ML), the development of nano-sized drug delivery systems, and the integration of IoT and wearable technology into drug delivery systems.
The increasing prevalence of chronic diseases is poised to drive the growth of the smart drug delivery systems market. Chronic diseases, characterized by long-term health conditions with slow progression and complex causes, are on the rise due to factors such as aging populations, environmental influences, and disparities in healthcare access. Smart drug delivery systems offer a promising solution for managing chronic diseases by enhancing medication effectiveness and improving patient adherence. For example, data from the National Library of Medicine forecasts a substantial increase in the number of individuals with at least one chronic illness by 2050, underscoring the significant role of rising chronic disease prevalence in propelling the smart drug delivery systems market.
Key players in the smart drug delivery systems market are focused on developing innovative reusable drug delivery devices to revolutionize drug administration. One such device is Qfinity, a reusable drug delivery device designed for subcutaneous self-administration of medication. Unlike single-use devices, Qfinity can be utilized for multiple injections, reducing waste and offering environmental benefits. For instance, Jabil Inc. launched Qfinity in May 2022, featuring the capability to handle over 100 injections per device and accommodating various pre-filled cartridges. The device not only reduces the carbon footprint per injection but also offers versatility in handling different drug volumes and viscosities. Additionally, the connected version, Qfinity+, enables remote monitoring of patient care and compliance through built-in sensors and electronics, ensuring connectivity without compromising ease of use.
In October 2023, Novo Nordisk A/S strengthened its position in the smart drug delivery systems market through the acquisition of Biocorp Production SA for $164.5 million. This strategic move aims to augment Novo Nordisk's capabilities in developing innovative connected devices and delivery solutions, exemplified by Mallya, a smart add-on device for pen injectors. Biocorp, a France-based designer and manufacturer of medical devices and drug delivery systems, brings expertise in connected devices that align with Novo Nordisk's focus on advancing drug delivery technologies to enhance patient care and treatment outcomes.
Major companies operating in the smart drug delivery systems market are Pfizer Inc, Johnson & Johnson, Bayer AG, Abbott Laboratories, Novartis International AG, Medtronic plc, Eli Lilly and Company, Amgen Inc, Novo Nordisk, Merck Group, Becton Dickinson and Company, Stryker Corporation, Baxter International Inc, Boston Scientific Corporation, Biogen Inc, Vertex Pharmaceuticals Incorporated, Phillips-Medisize Corporation, ResMed Inc., West Pharmaceutical Services Inc, Insulet Corporation, Owen Mumford Ltd, Sonceboz, H&T Presspart Manufacturing Ltd, E3D Elcam Drug Delivery Devices, CeQur Corporation.
North America was the largest region in the smart drug delivery systems market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the smart drug delivery systems market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the smart drug delivery systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Smart drug delivery systems encompass advanced technologies aimed at enhancing the efficacy, safety, and targeted delivery of pharmaceutical compounds within the body. These systems utilize diverse approaches to regulate drug release, improve bioavailability, and minimize adverse effects.
The primary products within smart drug delivery systems include connected inhalers, connected autoinjectors, connected pen injectors, connected wearable injectors, add-on sensors, and other related devices. Connected inhalers, for instance, are electronic monitoring systems integrated into inhalers, which track drug usage and may provide feedback on device technique. These systems find applications across various therapeutic areas such as metabolic disorders, neurological disorders, respiratory disorders, hormonal disorders, and more. They can deliver drugs via different modes including injectable, inhalation, and oral routes, and cater to a range of end users including hospitals, clinics, home care settings, ambulatory care facilities, among others.
The smart drug delivery systems market research report is one of a series of new reports that provides smart drug delivery systems market statistics, including smart drug delivery systems industry global market size, regional shares, competitors with smart drug delivery systems market share, detailed smart drug delivery systems market segments, market trends and opportunities, and any further data you may need to thrive in the smart drug delivery systems industry. This smart drug delivery systems market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The smart drug delivery systems market consists of revenues earned by entities by providing services such as personalized drug delivery, targeted treatment, diagnostic integration, remote monitoring, and feedback mechanisms. The market value includes the value of related goods sold by the service provider or included within the service offering. The smart drug delivery systems market also includes sales of products including microfluidic devices, transdermal drug delivery patches, electroceutical devices, and remote-controlled drug delivery devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
Executive Summary
Smart Drug Delivery Systems Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on smart drug delivery systems market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for smart drug delivery systems? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The smart drug delivery systems market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Product: Connected Inhalers; Connected Autoinjectors; Connected Pen Injectors; Connected Wearable Injectors; Add-On Sensors; Other Products.2) by Therapeutic Area: Metabolic Disorders; Neurological Disorders; Respiratory Disorders; Hormonal Disorders; Other Therapeutic Areas.
3) by Drug Delivery Mode: Injectable; Inhalation; Oral
4) by End-User: Hospitals; Clinics; Home Care; Ambulatory Care Settings; Other End-Users
Key Companies Mentioned: Pfizer Inc; Johnson & Johnson; Bayer AG; Abbott Laboratories; Novartis International AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc
- Johnson & Johnson
- Bayer AG
- Abbott Laboratories
- Novartis International AG
- Medtronic plc
- Eli Lilly and Company
- Amgen Inc
- Novo Nordisk
- Merck Group
- Becton Dickinson and Company
- Stryker Corporation
- Baxter International Inc
- Boston Scientific Corporation
- Biogen Inc
- Vertex Pharmaceuticals Incorporated
- Phillips-Medisize Corporation
- ResMed Inc
- West Pharmaceutical Services Inc
- Insulet Corporation
- Owen Mumford Ltd
- Sonceboz
- H&T Presspart Manufacturing Ltd
- E3D Elcam Drug Delivery Devices
- CeQur Corporation
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 175 |
Published | May 2024 |
Forecast Period | 2024 - 2028 |
Estimated Market Value ( USD | $ 12.65 Billion |
Forecasted Market Value ( USD | $ 25.94 Billion |
Compound Annual Growth Rate | 19.7% |
Regions Covered | Global |
No. of Companies Mentioned | 25 |